title: Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.
abstract: Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours "off" decreased at weeks 6 and 12 (p < 0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score "on" and "off" (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased; no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.
authors.affiliation: Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Pacchetti
authors.forename: E
authors.initials: E
authors.lastname: Martignoni
authors.forename: P
authors.initials: P
authors.lastname: Bruggi
authors.forename: L
authors.initials: L
authors.lastname: Godi
authors.forename: B
authors.initials: B
authors.lastname: Aufdembrinke
authors.forename: C
authors.initials: C
authors.lastname: Miltenburger
authors.forename: B
authors.initials: B
authors.lastname: Voet
authors.forename: G
authors.initials: G
authors.lastname: Nappi
mesh_terms: D000328:Adult; D000368:Aged; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
chemical_list: D015259:Dopamine Agents; D010919:Placebos; C006208:dironyl; D007980:Levodopa; D008090:Lisuride; D004298:Dopamine